{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:57:20Z","timestamp":1793735840036,"version":"4.6.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","derm.theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Dermatologic Clinics"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.det.2016.11.003","type":"journal-article","created":{"date-parts":[[2017,3,17]],"date-time":"2017-03-17T02:20:35Z","timestamp":1489717235000},"page":"129-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Skin Cancer Risk (Nonmelanoma Skin Cancers\/Melanoma) in Vitiligo Patients"],"prefix":"10.1016","volume":"35","author":[{"given":"Michelle","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.det.2016.11.003_bib1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","article-title":"Guidelines for the management of vitiligo: the European Dermatology Forum consensus","volume":"168","author":"Taieb","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib2","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","article-title":"A\u00a0review of the worldwide prevalence of vitiligo in children\/adolescents and adults","volume":"51","author":"Kruger","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5694\/j.1326-5377.2006.tb00086.x","article-title":"Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985","volume":"184","author":"Staples","year":"2006","journal-title":"Med J Aust"},{"key":"10.1016\/j.det.2016.11.003_bib4","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.294.12.1541","article-title":"Sun exposure, sun protection, and vitamin D","volume":"294","author":"Robinson","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.det.2016.11.003_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.amepre.2014.08.036","article-title":"Prevalence and costs of skin cancer treatment in the U.S., 2002-2006 and 2007-2011","volume":"48","author":"Guy","year":"2015","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.det.2016.11.003_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/1523-1747.ep12512500","article-title":"Some aspects of melanin biology: 1950-1975","volume":"67","author":"Jimbow","year":"1976","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jaad.2005.08.063","article-title":"Skin cancer in skin of color","volume":"55","author":"Gloster","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib8","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1056\/NEJMoa0908547","article-title":"Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo","volume":"362","author":"Jin","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2016.11.003_bib9","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/ng.411","article-title":"Genome-wide association study identifies three loci associated with melanoma risk","volume":"41","author":"Bishop","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.det.2016.11.003_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1468-3083.2006.01899.x","article-title":"Association of vitiligo with HLA-A2: a meta-analysis","volume":"21","author":"Liu","year":"2007","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2016.11.003_bib11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1111\/pcmr.12161","article-title":"Melanoma-associated leukoderma - immunology in black and white?","volume":"26","author":"Naveh","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.det.2016.11.003_bib12","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/j.jaad.2013.01.012","article-title":"Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma","volume":"69","author":"Alonso-Castro","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.det.2016.11.003_bib13","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cup.12735","article-title":"Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma","volume":"43","author":"Mochel","year":"2016","journal-title":"J\u00a0Cutan Pathol"},{"key":"10.1016\/j.det.2016.11.003_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab","volume":"152","author":"Hua","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1084\/jem.20081811","article-title":"CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance","volume":"206","author":"Friedline","year":"2009","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.det.2016.11.003_bib16","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune Checkpoint Blockade in Cancer Therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.det.2016.11.003_bib17","doi-asserted-by":"crossref","DOI":"10.1111\/pcmr.12076","article-title":"Vitiligo: the white armour?","author":"Taieb","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.det.2016.11.003_bib18","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2133.2008.08943.x","article-title":"A\u00a0clinical trial and molecular study of photoadaptation in vitiligo","volume":"160","author":"Hexsel","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib19","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/00015550410022203","article-title":"311 nm tolerance of vitiligo skin increases with\u00a0skin photo type","volume":"85","author":"Caron-Schreinemachers","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2016.11.003_bib20","first-page":"160","article-title":"Clinical practice. Vitiligo","volume":"360","author":"Taieb","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.det.2016.11.003_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2133.1988.tb07096.x","article-title":"A\u00a0new development in UVB phototherapy of psoriasis","volume":"119","author":"van Weelden","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib22","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2133.1988.tb03489.x","article-title":"311 nm UVB phototherapy\u2013an effective treatment for psoriasis","volume":"119","author":"Green","year":"1988","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib23","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1001\/archderm.143.5.578","article-title":"Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy","volume":"143","author":"Yones","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib24","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1001\/archderm.1997.03890480045006","article-title":"Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A","volume":"133","author":"Westerhof","year":"1997","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib25","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1468-3083.2006.01413.x","article-title":"Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo","volume":"20","author":"Parsad","year":"2006","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.det.2016.11.003_bib26","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1365-2133.2008.08776.x","article-title":"Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy","volume":"159","author":"Hearn","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib27","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/00015550410026948","article-title":"No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study","volume":"84","author":"Weischer","year":"2004","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2016.11.003_bib28","first-page":"191","article-title":"Chronic cutaneous effects of long-term psoralen and ultraviolet radiation therapy in patients with vitiligo","volume":"66","author":"Harrist","year":"1984","journal-title":"Natl Cancer Inst Monogr"},{"key":"10.1016\/j.det.2016.11.003_bib29","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2340\/0001555572305306","article-title":"PUVA treatment of vitiligo: a retrospective study of 59 patients","volume":"72","author":"Wildfang","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2016.11.003_bib30","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1001\/archderm.1995.01690180114025","article-title":"Cutaneous malignancies in patients treated with psoralen photochemotherapy (PUVA) for vitiligo","volume":"131","author":"Halder","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib31","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40272-013-0013-9","article-title":"Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations","volume":"15","author":"Carr","year":"2013","journal-title":"Paediatr Drugs"},{"issue":"7","key":"10.1016\/j.det.2016.11.003_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009864.pub2","article-title":"Topical tacrolimus for atopic dermatitis","author":"Cury Martins","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.det.2016.11.003_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1159\/000247693","article-title":"Vitiligo and cutaneous melanoma. A case study","volume":"183","author":"Schallreuter","year":"1991","journal-title":"Dermatologica"},{"key":"10.1016\/j.det.2016.11.003_bib34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0190-9622(83)70182-9","article-title":"Vitiligo in patients with metastatic melanoma: a good prognostic sign","volume":"9","author":"Nordlund","year":"1983","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib35","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jaad.2008.09.033","article-title":"Incidence of nonmelanoma skin cancer in a cohort of patients with vitiligo","volume":"60","author":"Hexsel","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib36","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2340\/00015555-2179","article-title":"Prediction of the Occurrence of Melanoma and Non-melanoma Skin Cancer in Patients with Vitiligo","volume":"96","author":"Hammoud","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2016.11.003_bib37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/000155598442944","article-title":"On the association between vitiligo and malignant melanoma","volume":"78","author":"Lindelof","year":"1998","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.det.2016.11.003_bib38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000057881","article-title":"Decreased photodamage and low incidence of non-melanoma skin cancer in 136 sun-exposed caucasian patients with vitiligo","volume":"204","author":"Schallreuter","year":"2002","journal-title":"Dermatology"},{"key":"10.1016\/j.det.2016.11.003_bib39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjd.12111","article-title":"Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners","volume":"168","author":"Teulings","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib40","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jaad.2011.10.022","article-title":"Long-term prognosis of vitiligo patients on narrowband UVB phototherapy","volume":"66","author":"Park","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib41","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.jaad.2014.07.050","article-title":"Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo","volume":"71","author":"Paradisi","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-4632.2004.02186.x","article-title":"UVB phototherapy and skin cancer risk: a review of the literature","volume":"44","author":"Lee","year":"2005","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib43","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000249197","article-title":"Long-term actinic damage in sun-exposed vitiligo and normally pigmented skin","volume":"174","author":"Calanchini-Postizzi","year":"1987","journal-title":"Dermatologica"},{"key":"10.1016\/j.det.2016.11.003_bib44","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1096\/fj.09-132621","article-title":"Enhanced DNA binding capacity on up-regulated epidermal wild-type p53 in vitiligo by H2O2-mediated oxidation: a possible repair mechanism for DNA damage","volume":"23","author":"Salem","year":"2009","journal-title":"FASEB J"},{"key":"10.1016\/j.det.2016.11.003_bib45","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1034\/j.1600-0625.2003.00084.x","article-title":"Increased epidermal functioning wild-type p53 expression in vitiligo","volume":"12","author":"Schallreuter","year":"2003","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib46","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2009.06.072","article-title":"Nonmelanoma skin cancer in vitiligo patients","volume":"61","author":"Nordlund","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.det.2016.11.003_bib47","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/s00403-011-1165-5","article-title":"Why vitiligo is associated with fewer risk of skin cancer?: providing a molecular mechanism","volume":"303","author":"Feily","year":"2011","journal-title":"Arch Dermatol Res"}],"container-title":["Dermatologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863516301309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733863516301309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T17:44:23Z","timestamp":1692726263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733863516301309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S0733863516301309"],"URL":"https:\/\/doi.org\/10.1016\/j.det.2016.11.003","relation":{},"ISSN":["0733-8635"],"issn-type":[{"value":"0733-8635","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skin Cancer Risk (Nonmelanoma Skin Cancers\/Melanoma) in Vitiligo Patients","name":"articletitle","label":"Article Title"},{"value":"Dermatologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.det.2016.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}